Your browser doesn't support javascript.
loading
Clinical observation of esomeprazole combined with trimebutine on treatment of non-erosive reflux disease / 中国综合临床
Clinical Medicine of China ; (12): 168-170, 2014.
Article in Chinese | WPRIM | ID: wpr-444249
ABSTRACT
Objective To investigate the effect and recurrence of the esomeprazole combined with trimebutine on treatment for non-erosive reflux disease(NERD).Methods One hundred and twenty-five cases of patients with NERD were randomly divided into the treatment group (n =62) and the control group (n =63).Patients in treatment group were received the esomeprazole 20 mg,twice a day and trimebutine 0.2 g,3 times a day,in control group were received the esomeprazole 20 mg,twice a day and mosapride 5 mg,3 times a day.After 8 weeks treatment,6 months follow-up was conducted and the effects and recurrence were evaluated.Results The clinical curative rates at 4th and 8th weeks treatment in treatment group were 75.8% (47/62) and 95.2% (59/62),higher than that of control group (57.1% (36/63),x2 =4.879,P =0.027 ; 84.1% (53/63),x2 =4.083,P =0.043).The GERDQ curative rates at 4th and 8th weeks treatment in treatment group were 72.6% (45/62),93.5% (58/62) respectively,significantly higher than that of the control group (52.4% (33/ 63),x2 =5.434,P =0.020 ; 79.4% (50/63),x2 =5.350,P =0.021).The recurrence rates of 6 months followup were 77.4% (48/62) in the treatment group and 81.0% (51/63) in the control group,there was no significant difference between the two groups (P =0.627).Conclusion Esomeprazole combined with trimebutine is safe and effective treatment on non-erosive reflux disease,and the recurrence rates was lower than that in the control group.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Clinical Medicine of China Year: 2014 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Clinical Medicine of China Year: 2014 Type: Article